Name: Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?
Uploaded: 2022-01-31T00:00:00.000Z
Description: Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Atopic Dermatitis

We have seen boxed warning now, both with our topical agent topical ruxalitinib, as well as the two newly approved agents for moderate to severe atopic dermatitis, which are systemic jack inhibitors eupidocitinib and abrucitinib. The boxed warning as it pertains to topical ruxalitinib is is really a bleed over from the systemic warning label language and really has to do with risks associated with systemic use, really in populations outside of atopic dermatitis, rather than being derived from the topical rexalitinib data itself.

Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Related CME